Caribou Biosciences, Inc.
CRBU
Rank in Stocks
#23167
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm... Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.
Share Price
$0.4198
Last synced: 2026-11-09
Market Cap
$45.01M
Change (1 day)
-6.44%
Change (1 year)
-81.26%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Caribou Biosciences, Inc. (CRBU)
Category
Healthcare
EPS for Caribou Biosciences, Inc. (CRBU)
EPS as of September 2026 TTM: $-1.03
According to Caribou Biosciences, Inc.'s latest financial reports, its current EPS (TTM) is $-1.03. At the end of 2025 the company had an EPS of $-1.59, an increase over its 2024 EPS of $-1.65.
EPS history for Caribou Biosciences, Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.03 | -35.22% |
| 2025 | $-1.59 | -3.64% |
| 2024 | $-1.65 | 19.57% |
| 2023 | $-1.38 | -15.85% |
| 2022 | $-1.64 | 47.75% |
| 2021 | $-1.11 | -10.48% |
| 2020 | $-1.24 | 45.88% |
| 2019 | $-0.85 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,620.39% |
US
|
|
| $-7.07 | 586.41% |
US
|
|
| $-5.29 | 413.59% |
AU
|
|
| $12.88 | -1,350.50% |
BE
|
|
| $21.56 | -2,193.20% |
NL
|
Questions about Caribou Biosciences, Inc.'s earnings per share (EPS)
What is Caribou Biosciences, Inc.'s earnings per share (EPS)?
Caribou Biosciences, Inc.'s earnings per share (EPS) over the last twelve months is $-1.03, as of Sep 2026.
What was Caribou Biosciences, Inc.'s earnings per share (EPS) in 2025?
In 2025, Caribou Biosciences, Inc.'s earnings per share (EPS) was $-1.59, compared with $-1.65 in 2024.
How has Caribou Biosciences, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Caribou Biosciences, Inc.'s earnings per share (EPS) was highest in 2021 ($-1.11) and lowest in 2024 ($-1.65).
How does Caribou Biosciences, Inc.'s earnings per share (EPS) compare with similar companies?
Caribou Biosciences, Inc.'s earnings per share (EPS) ($-1.03) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.